TMEscore is a prognostic biomarker and predicts immunotherapeutic benefit. TMEscore is a prognostic biomarker and predicts immunotherapeutic benefit. A,

Slides:

Advertisements

Similar presentations

Date of download: 5/28/2016 From: Association Between Exposure to Low to Moderate Arsenic Levels and Incident Cardiovascular Disease: A Prospective Cohort.

Advertisements

Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Adjuvant Chemotherapy With Gemcitabine and Long-term.

Date of download: 6/24/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association Between Iodinated Contrast Media Exposure.

H. Mansell, L.J. Worobetz, T. Sylwestrowicz, A.S. Shoker

POD1 ALP (IU/L) ALP POD7 p <

From: Perioperative Use of Dobutamine in Cardiac Surgery and Adverse Cardiac Outcome:Propensity-adjusted Analyses Anesthes. 2008;108(6): doi: /ALN.0b013e f.

ASPEN: Prolonged PFS With Sunitinib vs Everolimus in Nonclear-Cell RCC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 -

Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non- small-cell lung cancer (NSCLC) patients with good performance status.

MicroRNAs for the Prediction of Early Response to Sorafenib Treatment in Human Hepatocellular Carcinoma Liver Cancer 2017;6: DOI: /

Urinary ammonia and long-term outcomes in chronic kidney disease

Volume 33, Issue 5, Pages e4 (May 2018)

Volume 68, Issue 1, Pages (July 2015)

Frequency of JAK1 and JAK2 alterations and their association with overall survival in TCGA datasets. Frequency of JAK1 and JAK2 alterations and their association.

Plasma active glucagon-like peptide-1 (GLP-1) response in patients with type 2 diabetes during the liquid high-fat meal test at baseline, 12 weeks and.

Graph (box plots) shows primary tumor volumes of oral and maxillary sinus (A) and pharyngeal (B) cancers categorized at T1–T4. Graph (box plots) shows.

Response to Carfilzomib Therapy

David D. Shersher, MD, Michael S

Heiko Lehrmann et al. JACEP 2018;j.jacep

Kaplan–Meier survival curves of all-cause mortality in patients with idiopathic pulmonary fibrosis (IPF). Kaplan–Meier survival curves of all-cause mortality.

The progression of chronic kidney disease: A 10-year population-based study of the effects of gender and age B.O. Eriksen, O.C. Ingebretsen Kidney International

Serum DNA Motifs Predict Disease and Clinical Status in Multiple Sclerosis Julia Beck, Howard B. Urnovitz, Marina Saresella, Domenico Caputo, Mario Clerici,

Prognostic Impact of Circulating Tumor Cells in Patients with Small Cell Lung Cancer Tateaki Naito, MD, PhD, Fumihiro Tanaka, MD, PhD, Akira Ono, MD,

Characteristics of the Patients at Baseline*

A and B, ROC curves of the proteomics panel diagnosis.

Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS by Takeshi Sugio, Kohta Miyawaki, Koji Kato, Kensuke Sasaki, Kyohei Yamada,

Simon W. Rabkin et al. JACEP 2017;3:

Figure 1. Survival curves from a hypothesized clinical trial randomizing patient to standard of care with and without ... Figure 1. Survival curves from.

Circulating Serum Vascular Endothelial Growth Factor is Not a Prognostic Factor of Non-small Cell Lung Cancer Mohammad Chakra, MD, Jean Louis Pujol,

Box plot of acquisition times across the various study cohorts.

Figure 1. Identification of three tumour molecular subtypes in CIT and TCGA cohorts. We used CIT multi-omics data ( Figure 1. Identification of.

Transcription/abundance ratios (logarithmic scale) of OTUs, ZOTUs, and population genomes of selected microbial orders. Transcription/abundance ratios.

Fig. 3. Improved clinical responses to CD19 CAR-T cell immunotherapy after Cy/Flu lymphodepletion. Improved clinical responses to CD19 CAR-T cell immunotherapy.

American Journal of Kidney Diseases

Breadth of antigen response as a correlate of protection.

Effect of randomized treatment on all renal events (top) and the composite of all renal events, macrovascular events, or all-cause mortality (bottom) according.

MiR-520d-3p is an independent positive prognostic factor in ovarian cancer. miR-520d-3p is an independent positive prognostic factor in ovarian cancer.

Association between RB pathway alterations and poor prognosis in early-stage lung adenocarcinoma patients. Association between RB pathway alterations and.

Progastrin expression in colonic tissues and Kaplan–Meier survival curves. Progastrin expression in colonic tissues and Kaplan–Meier survival curves. A,

PD-L1 expression correlates with T-cell markers and an IFN response signature in human melanomas. PD-L1 expression correlates with T-cell markers and an.

Landscape of the TME in gastric cancer and characteristics of TME subtypes. Landscape of the TME in gastric cancer and characteristics of TME subtypes.

Immune signatures of patients with short-, medium-, and long-term survival. Immune signatures of patients with short-, medium-, and long-term survival.

CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated with a longer survival. CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated.

Fig. 1. Classification of the Kaplan-Meier curves and Cox survival estimates for the OS of patients using the pSPC in Cohort_C and in the overall population.

Immune activity and neopeptide load correlate across tumor types.

Time to onset of hypothyroidism after first treatment with immune checkpoint inhibitors in the combination therapy and monotherapy groups. Time to onset.

Among three residual kidney function (RKF) indices, only residual urine volume (UV) indicated an independent prognostic value in patients with UV≥0.1 or.

Kaplan–Meier curves for PFS and OS (for patients treated with anti-PD-1/PD-L1 monotherapy). Kaplan–Meier curves for PFS and OS (for patients treated with.

Linear correlationa between TMB cutoff for ORb for CR/PR rates and HRc for PFS, and OS depending on TMB for patients treated with anti-PD-1/PD-L1 monotherapy.

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

Survival risk prediction analysis and application of the metastasis gene signature. Survival risk prediction analysis and application of the metastasis.

PD-1 expression in ovarian cancer.

Influence of ASGR2 expression on survival.

Correlation of PTEN loss in melanoma cells with an immune resistance phenotype. Correlation of PTEN loss in melanoma cells with an immune resistance phenotype.

Genomic determinants of response to cytotoxic chemotherapy.

Fig. 5 Proportions of EpCAM+ systemic tumor cells correlate with the clinical outcome of patients with MBC. Proportions of EpCAM+ systemic tumor cells.

One-year costs by evaluation strategy.

Patient stratification using survival risk prediction and BCLC staging

Progression and survival analysis.

Boxplots of diffusion (A and B) and perfusion (C) characteristics in brain metastases (gray), glioblastomas (white), and PCLs (dotted). Boxplots of diffusion.

STK11/LKB1 comutations are associated with inferior objective response rate with PD-1 blockade in KRAS-mutant LUAC. A, Objective response rate (RECISTv1.1)

Fecal calprotectin and alpha-1 antitrypsin predict severity and response to corticosteroids in gastrointestinal graft-versus-host disease by Paula Rodriguez-Otero,

Transcriptome traits and clinical characteristics of TME phenotypes in the ACRG cohort. Transcriptome traits and clinical characteristics of TME phenotypes.

TME characteristics of TCGA-STAD subtype and cancer somatic genome.

STK11/LKB1 genetic alterations are associated with shorter progression-free and overall survival with PD-1 blockade among KRAS-mutant LUAC in the SU2C.

Coincidence and prognostic significance of PD-1+ and CD103+ cells in HGSC. Serial sections from the 490-case TMA were stained with antibodies to CD103.

Construction of TME signatures and functional annotation.

Intersubject distribution of eGFR slope (left) and mGFR slope (right).

* OS >3yr with No Next Line * * * * *

Mean nasopharyngeal pressure during high-flow oxygen therapy, with mouth open or closed. Mean nasopharyngeal pressure during high-flow oxygen therapy,

GSN and DNMT1 expression are inversely correlated in a pattern associated with patient survival. GSN and DNMT1 expression are inversely correlated in a.

Presentation transcript:

TMEscore is a prognostic biomarker and predicts immunotherapeutic benefit. TMEscore is a prognostic biomarker and predicts immunotherapeutic benefit. A, Subgroup analyses estimating clinical prognostic value between low/high TMEscore groups in independent gastric cancer data sets and cancer stage. The length of the horizontal line represents the 95% confidence interval for each group. The vertical dotted line represents the hazard ratio (HR) of all patients. The vertical solid line represents HR = 1. HR < 1.0 indicate that high TMEscore is a favorable prognostic biomarker. Number of patients indicated. B, Subgroup analyses estimating prognostic value of TMEscore in different cancer types from TCGA data sets. The length of horizontal line represents the 95% confidence interval for each group. The vertical dotted line represents the HR of all patients. The vertical solid line represents HR = 1. HR < 1.0 indicates that high TMEscore is a favorable prognostic biomarker. Number of patients is indicated. C, Kaplan–Meier curves for patients with high (n = 88) and low (n = 209) TMEscores in the IMvigor210 cohort. Log-rank test shows an overall P = 0.008. D, Rate of clinical response (complete response [CR]/partial response [PR] and stable disease [SD]/progressive disease [PD]) to anti–PD-L1 immunotherapy in high or low TMEscore groups in the IMvigor210 cohort (two-sided Fisher exact test, P < 0.001). Patients with high TMEscores: response (n = 33) and nonresponse (n = 55); patients with low TMEscores: response (n = 35) and nonresponse (n = 175). E, Distribution of TMEscores in groups with different anti–PD-L1 clinical response statuses (CR: n = 25; PR: n = 43; SD: n = 63; PD: n = 167). The thick line represents the median value. The bottom and top of the boxes are the 25th and 75th percentiles (interquartile range). The whiskers encompass 1.5 times the interquartile range. The differences among groups were compared through the Kruskal–Wallis test (Kruskal–Wallis, P = 0.004). P values are indicated. F, ROC curves measuring the predictive value of the TMEscore, TMB, and combination of TMEscore and TMB in the IMvigor210 cohort (N = 298). The area under the ROC curve was 0.624, 0.623, and 0.700 for the TMEscore, TMB, and TMEscore combined with TMB, respectively. Likelihood ratio test, P = 0.019, and 0.004, respectively. G, Kaplan–Meier curves for patients with high (n = 21) and low (n = 6) TMEscores in the GSE78220 cohort. Log-rank test shows an overall P = 0.021. H, Rate of clinical response (CR/PR, SD/PD) to anti–PD-1 immunotherapy in high or low TMEscore groups in the GSE78220 cohort. Patients with high TMEscores: response (n = 14) and nonresponse (n = 7). Patients with low TMEscores: response (n = 0) and nonresponse (n = 6). Two-sided Fisher exact test, P = 0.006. I, TMEscores in groups with different anti–PD-1 clinical response status (CR/PR: n = 14; SD/PD: n = 13). The thick line represents the median value. The bottom and top of the boxes are the 25th and 75th percentiles (interquartile range). The whiskers encompass 1.5 times the interquartile range. The differences between groups were compared through the Wilcoxon test (Wilcoxon, P = 0.031). J, The predictive value of the TMEscore measured by ROC curves in the GSE78220 cohort (N = 27). The AUC is 0.731. Dongqiang Zeng et al. Cancer Immunol Res 2019;7:737-750 ©2019 by American Association for Cancer Research